2. Academic Validation
  3. Development of Quinazoline/Pyrimidine-2,4(1 H,3 H)-diones as Agonists of Cannabinoid Receptor Type 2

Development of Quinazoline/Pyrimidine-2,4(1 H,3 H)-diones as Agonists of Cannabinoid Receptor Type 2

  • ACS Med Chem Lett. 2017 May 1;8(6):678-681. doi: 10.1021/acsmedchemlett.7b00007.
Hai-Yan Qian 1,  Zhi-Long Wang 2,  You-Lu Pan 1,  Li-Li Chen 1,  Xin Xie 2,  Jian-Zhong Chen 1
Affiliations

Affiliations

  • 1 College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China.
  • 2 CAS Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China.
PMID: 28626532 DOI: 10.1021/acsmedchemlett.7b00007
Abstract

Starting from a prototypical structure 1, we describe our efforts to design and obtain novel quinazoline/pyrimidine-2,4(1H,3H)-diones with high CB2 Agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, 8 and 36, in this series were also endowed with lower logP values than that of GW842166X and lead compound 1. These derivatives appear to be promising lead compounds for the development of future CB2 agonists.

Keywords

CB2 agonist; Cannabinoid receptors; molecular modeling; structure−activity relationship.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z